Extended Field Radiation Therapy Versus Delayed Hormonal Therapy in Node Positive Prostatic Adenocarcinoma
- 30 April 1982
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 127 (5), 935-937
- https://doi.org/10.1016/s0022-5347(17)54136-1
Abstract
The disease control and survival advantage of either extended field megavoltage irradiation or delayed androgen ablation in a randomized [human] clinical trial were determined. Comparison of the 2 treatments, using either time to 1st evidence of treatment failure or survival, demonstrates an advantage to extended field radiation.This publication has 5 references indexed in Scilit:
- Prognosis of Patients With Stage D1 Prostatic AdenocarcinomaJournal of Urology, 1981
- Prostatic Adenocarcinoma: Relationship of Grade and Local Extent to the Pattern of MetastasesJournal of Urology, 1977
- Implantation of 125I in Prostatic CancerSurgical Clinics of North America, 1974
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958